Que es MABEL y cuando se usa?

Minimal Anticipated Biological Effect Level. La dosis mas baja esperada que cause efecto farmacologico en humanos. Se usa cuando el mecanismo de accion tiene potencial de toxicidad seria (ej. agonistas de receptores inmunes). Es mas conservador que NOAEL para biologicos con pharmacologia relevante para seguridad.

Como se calcula HED desde NOAEL?

Human Equivalent Dose = NOAEL (mg/kg) x (Animal Km / Human Km). Km es factor de conversion basado en superficie corporal. Rata: 6, Perro: 20, Humano: 37. Se aplica luego factor de seguridad (tipicamente 10). Ejemplo: NOAEL rata 10 mg/kg -> HED = 10 x (6/37) = 1.6 mg/kg -> Starting dose = 0.16 mg/kg.

Que es sentinel dosing?

Administrar el farmaco primero a un solo sujeto antes de los demas del cohorte. Reduce riesgo si hay reaccion inesperada severa. Solo un sujeto expuesto inicialmente. Si tolera, se dosifican los demas. Estandar en estudios fase 1 con farmacos nuevos.

Que diferencia hay entre SAD y MAD?

SAD (Single Ascending Dose): dosis unica, observa efectos agudos, establece rango de dosis unica. MAD (Multiple Ascending Dose): dosis multiples sobre varios dias, evalua acumulacion, steady-state, tolerabilidad cronica. MAD sigue tipicamente a SAD exitoso.

Ensayos Clinicos Fase 1 de Peptidos

Categorías: Metodología de Investigación, Información General

Los ensayos fase 1 son la primera administracion de un peptido terapeutico en humanos. Su objetivo principal es evaluar seguridad y PK.

Resumen Simplificado

Fase 1 evalua seguridad, tolerabilidad, PK y establece rango de dosis para estudios posteriores.

Objetivos de fase 1

Phase 1 has defined objectives. Primary. Safety assessment. Tolerability. Adverse events. Serious adverse events. Dose-limiting toxicities. Maximum tolerated dose. MTD. Secondary. Pharmacokinetics. Absorption. Distribution. Metabolism. Excretion. PK parameters. Cmax, Tmax, AUC. Half-life. Clearance. Volume. Pharmacodynamics. If applicable. Biomarkers. Target engagement. Exploratory. Dose-response. Food effect. Drug interactions. Special populations. Renal impairment. Hepatic impairment. Objectives drive. Study design. Endpoints. Sample size. Analysis plan. Regulatory requirements. Must be addressed. IND content. Protocol design. Justification. For each objective. Clear definition. Before study start. Phase 1 is foundation. For development. Data inform. Later phases. Safety profile. Guides monitoring. PK data. Predict dosing. PD data. Suggest efficacy. Quality data. Is essential. For success. In later phases.

Diseno de estudios

Study design is critical. Types. Single ascending dose. SAD. Multiple ascending dose. MAD. Food effect. Drug-drug interaction. Bioavailability. Special populations. SAD design. Cohorts. Of subjects. Typically healthy. Sequential dosing. Starting dose. From preclinical. Escalation. Based on. Safety and PK. Sentinel dosing. First subject. Before others. In each cohort. MAD design. Multiple days. Of dosing. Typically 7-14 days. Assess accumulation. Steady-state. Longer duration. Than SAD. Food effect. Fed vs fasted. Crossover. Same subjects. Both conditions. DDI studies. Perpetrator. Victim. Assessment. In vitro data. Guide design. Randomization. Placebo-controlled. Standard. Double-blind. Preferred. Open-label. Sometimes used. Sample size. Typically 6-8 active. 2-3 placebo. Per cohort. Number of cohorts. Depends on. Dose range. Safety findings. Stopping criteria. Pre-defined. Safety limits. PK limits. Sponsor decision. Design determines. Data quality. Must be. Thoughtful. Justified. Documented. Regulatory approval. Before initiation. Ethics review. Informed consent. Essential.

Seleccion de sujetos

Subject selection affects outcomes. Population. Healthy volunteers. Most common. For phase 1. Patients. If safety concerns. In healthy. Or if target. Only in disease. Age range. Typically 18-55. For healthy studies. Older patients. May be needed. For age-related. Conditions. Gender. Both genders. Unless justified. Pregnancy testing. For women. Of childbearing potential. Contraception required. Inclusion criteria. Good health. Normal labs. Normal ECG. Normal exam. BMI range. Typically 18-32. Willingness. To participate. Compliance expected. Exclusion criteria. Significant disease. Abnormal labs. Abnormal ECG. Medications. Concurrent drugs. Allergies. To drug components. History. Of relevant conditions. Substance use. Alcohol. Recreational drugs. Pregnancy. Or breastfeeding. Screening. Medical history. Physical exam. Laboratory tests. ECG. Sometimes imaging. Washout period. For prior medications. Selection criteria. Must be. Clear. Justified. Enforceable. Too restrictive. Recruitment difficult. Too permissive. Heterogeneous population. Variable results. Balance is key.

Determinacion de dosis inicial

Starting dose is critical decision. Approaches. NOAEL-based. From toxicology. Most conservative. HED calculation. Human equivalent dose. Allometric scaling. Body surface area. Safety factor. Typically 10x. Applied to HED. MABEL approach. Minimal anticipated biological effect level. For biologics. Including peptides. When pharmacology. Is relevant. For safety. PAD approach. Pharmacologically active dose. If known. From clinical. Experience. Considerations. Mode of action. Target. Expected effects. Safety signals. In animals. Severity. Reversibility. NOAEL vs PAD. Whichever is lower. Should be used. As starting point. Regulatory guidance. ICH E4. FDA guidance. For biologics. EMA guidance. Case-by-case. Justification required. In protocol. In IND. Conservative approach. Is preferred. Can always. Increase dose. Cannot undo. Safety event. Escalation scheme. Pre-defined. Dose levels. Increments. Stop criteria. Starting dose. Is foundation. For entire. Escalation. Must be. Safe. Justified. Documented. Regulatory agreement. Recommended. Before proceeding.

Evaluacion de seguridad

Safety evaluation is primary. Adverse events. Collection. Throughout study. Post-dosing period. Grading. CTCAE criteria. Standard. Severity scale. Relationship to drug. Assessment. Causality. Serious adverse events. Definition. Death. Life-threatening. Hospitalization. Disability. Important medical event. Prompt reporting. To sponsor. To regulators. Safety monitoring. Vital signs. Blood pressure. Heart rate. Temperature. Respiratory rate. Laboratory tests. Hematology. Clinical chemistry. Urinalysis. Special tests. As indicated. By target organ. ECG. Standard. Continuous. If cardiac concern. Holter monitoring. Physical examination. Pre and post. Study duration. Immunogenicity. For peptides. ADA testing. Neutralizing antibodies. Timing. Baseline. During study. Follow-up. Safety committee. Review data. Make decisions. Escalation. Stopping. Independent. Preferred. DLT definition. Dose-limiting toxicity. Pre-defined. Guides escalation. Stopping rules. Explicit criteria. When to stop. Escalation. Or study. Safety is paramount. Cannot be compromised. Data collection. Must be complete. Accurate. Timely. Reporting. Must be. Prompt. Complete. Safety signals. Must be. Investigated. Characterized. Communicated.

Analisis farmacocinetico

PK analysis is standard. Sample collection. Serial sampling. Blood. Plasma. Or serum. Urine. If relevant. For excretion. Tissue. Rarely. Sampling schedule. Early timepoints. Distribution. Mid timepoints. Peak. Late timepoints. Elimination. Duration. 4-5 half-lives. Minimum. Rich sampling. For good. Characterization. Sparse sampling. For MAD. At steady-state. Bioanalysis. Validated method. LLOQ. Sufficient. Accuracy. Precision. Stability. Freezer storage. Freeze-thaw. Parameters calculated. Cmax. Maximum concentration. Tmax. Time to Cmax. AUC. Area under curve. Exposure measure. AUC0-t. AUC0-inf. Half-life. Terminal. t1/2. Clearance. CL. For IV. CL/F. For extravascular. Volume. Vd. Or Vd/F. Bioavailability. If compared. To IV. Non-compartmental. Standard approach. Compartmental. If needed. For prediction. PK/PD. Relationship. If PD data available. Modeling. Simulation. Dose prediction. Population PK. If data permit. Variability. Inter-subject. Intra-subject. Assessment. PK data. Are critical. For understanding. Drug behavior. Guide dosing. In later phases. Regulatory requirement. For approval. Quality data. Essential. Proper design. Execution. Analysis. Reporting.

Hallazgos Clave

Fase 1 evalua seguridad, tolerabilidad y PK como objetivos primarios
El diseno incluye SAD, MAD, food effect y estudios de poblaciones especiales
La seleccion de sujetos tipicamente es voluntarios sanos 18-55 anos
La dosis inicial se calcula desde NOAEL con factor de seguridad 10x o MABEL
La evaluacion de seguridad incluye AEs, laboratorio, ECG e inmunogenicidad
El analisis PK determina parametros como Cmax, AUC, half-life y clearance

Más artículos en Metodología de Investigación

Más artículos en Información General

Preguntas frecuentes

Que es MABEL y cuando se usa?: Minimal Anticipated Biological Effect Level. La dosis mas baja esperada que cause efecto farmacologico en humanos. Se usa cuando el mecanismo de accion tiene potencial de toxicidad seria (ej. agonistas de receptores inmunes). Es mas conservador que NOAEL para biologicos con pharmacologia relevante para seguridad.
Como se calcula HED desde NOAEL?: Human Equivalent Dose = NOAEL (mg/kg) x (Animal Km / Human Km). Km es factor de conversion basado en superficie corporal. Rata: 6, Perro: 20, Humano: 37. Se aplica luego factor de seguridad (tipicamente 10). Ejemplo: NOAEL rata 10 mg/kg -> HED = 10 x (6/37) = 1.6 mg/kg -> Starting dose = 0.16 mg/kg.
Que es sentinel dosing?: Administrar el farmaco primero a un solo sujeto antes de los demas del cohorte. Reduce riesgo si hay reaccion inesperada severa. Solo un sujeto expuesto inicialmente. Si tolera, se dosifican los demas. Estandar en estudios fase 1 con farmacos nuevos.
Que diferencia hay entre SAD y MAD?: SAD (Single Ascending Dose): dosis unica, observa efectos agudos, establece rango de dosis unica. MAD (Multiple Ascending Dose): dosis multiples sobre varios dias, evalua acumulacion, steady-state, tolerabilidad cronica. MAD sigue tipicamente a SAD exitoso.

Volver a la biblioteca de investigación